1
|
Pan X, He H, Bao Y, Bi Y, Chen L, Chen X, Fang H, Feng W, Gao L, Guo L, Guo Y, Han Y, Hua Q, Li N, Li Q, Li Y, Li Y, Li X, Liu J, Ma H, Mu J, Nong K, Shang H, Shen Y, Shi Z, Sun F, Sun N, Tao J, Wang J, Wang X, Wu J, Xiao X, Xie L, Xu J, Xu J, Ye H, Yu D, Yuan H, Zhang H, Zhang J, Zhang L, Zhang Y, Zhou J, Zhou X, Zhu D, Zhu T, Li S, Zhu Z. Chinese expert consensus on the management of hypertension in adults with type 2 diabetes. J Evid Based Med 2024; 17:851-864. [PMID: 39529557 DOI: 10.1111/jebm.12655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/07/2024] [Accepted: 10/09/2024] [Indexed: 11/16/2024]
Abstract
Both hypertension and type 2 diabetes are attributable to premature death, cardiovascular and kidney diseases with largely overlapping population. Followed the GRADE approach, this expert consensus aimed to reduce the cardiovascular and kidney death and disability due to hypertension and minimize the treatment burden in adults with type 2 diabetes. Through online survey and discussion, a multidisciplinary team comprehensively prioritized seven key guideline questions. Informed by the evidence synthesis and online discussion, the team developed 12 recommendations under the GRADE Evidence-to-decision (EtD) framework. The recommendations covered the screening of hypertension in adults diagnosed with type 2 diabetes but not hypertension and the monitoring, lifestyle interventions, and medications in those diagnosed with type 2 diabetes and hypertension.
Collapse
Affiliation(s)
- Xiaohui Pan
- Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China
| | - Hongbo He
- Department of Hypertension and Endocrinology, Army Medical University, Chongqing, China
- Chongqing Institute of Hypertension, Chongqing, China
| | - Yuqian Bao
- Department of Endocrinology and Metabolism, Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Yan Bi
- Department of Endocrinology, Affiliated Drum Tower Hospital, Nanjing University School of Medicine, Nanjing, China
| | - Luyuan Chen
- Department of Cardiology, People's Hospital of Guangdong Province, Guangzhou, China
- Guangdong Institute of Cardiovascular Disease, Guangzhou, China
| | - Xiaoping Chen
- Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China
| | - Hui Fang
- Department of Endocrinology, Tangshan Gongren Hospital Affiliated to Hebei Medical University, Tangshan, China
| | - Wenhuan Feng
- Department of Endocrinology, Affiliated Drum Tower Hospital, Nanjing University School of Medicine, Nanjing, China
| | - Ling Gao
- Department of Endocrinology, Renmin Hospital of Wuhan University, Wuhan, China
| | - Lixin Guo
- Department of Endocrinology, Beijing Hospital of the Ministry of Health, Beijing, China
- National Center of Geriatics and Gerotology, Beijing, China
- Institute of Geriatrics, Chinese Academy of Medical Sciences, Beijing, China
| | - Yifang Guo
- Department of Geriatric Cardiovascular Medicine, Hebei General Hospital, Shijiazhuang, China
| | - Yaling Han
- Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China
- Military Cardiovascular Disease Research Institute, Shenyang, China
| | - Qi Hua
- Department of Cardiology, Xuanwu Hospital, Capital Medical University, Beijing, China
| | - Nanfang Li
- Hypertension Diagnosis and Treatment Research Center, Xinjiang Uygur Autonomous Region People's Hospital, Urumqi, China
| | - Quanmin Li
- Department of Endocrinology, PLA Rocket Force Characteristic Medical Center, Beijing, China
| | - Yan Li
- Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
- Shanghai Institute of Hypertension, Shanghai, China
| | - Yong Li
- Department of Cardiology, Huashan Hospital, Fudan University, Shanghai, China
| | - Xialian Li
- Department of Endocrinology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Jing Liu
- Department of Cardiovascular Medicine, Peking University People's Hospital, Beijing, China
| | - Huijuan Ma
- Department of Endocrinology, The First Affiliated Hospital of Hebei Medical University, Shijiazhuang, China
| | - Jianjun Mu
- Department of Cardiovascular Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
| | - Kailei Nong
- Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China
| | - Huiqian Shang
- Department of Cardiovascular Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, China
| | - Yunfeng Shen
- Department of Endocrinology and Metabolism, The Eighth Affiliated Hospital of Sun Yat-Sen University, Shenzhen, China
| | - Zhongwei Shi
- Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Fang Sun
- Department of Hypertension and Endocrinology, Daping Hospital, Army Special Medical Center, Army Medical University, Chongqing, China
| | - Ningling Sun
- Department of Cardiovascular Medicine, Peking University People's Hospital, Beijing, China
| | - Jun Tao
- Department of Cardiology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
| | - Jiguang Wang
- Shanghai Institute of Hypertension, Shanghai, China
- Department of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Xinling Wang
- Department of endocrinology, Xinjiang Uygur Autonomous Region People's Hospital, Urumqi, China
| | - Jing Wu
- Department of Endocrinology, Xiangya Hospital of Central South University, Changsha, China
| | - Xinhua Xiao
- Department of Endocrinology and Metabolism, First Affiliated Hospital of University of South China, Hengyang, China
| | - Liangdi Xie
- Department of Cardiovascular Medicine, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China
| | - Jing Xu
- Department of Endocrinology, Second Affiliated Hospital of Xi'an Jiaotong University, X''an, China
| | - Jing Xu
- Department of Endocrinology, Xinqiao Hospital, Army Medical University, Chongqing, China
| | - Hongying Ye
- Department of Endocrinology, Huashan Hospital, Fudan University, Shanghai, China
| | - Dongni Yu
- Department of Endocrinology, Beijing Hospital of the Ministry of Health, Beijing, China
| | - Hong Yuan
- Department of Cardiology, Third Xiangya Hospital of Central South University, Changsha, China
| | - Huijie Zhang
- Department of Endocrinology, Nanfang Hospital, Southern Medical University, Guangzhou, China
| | - Jian Zhang
- Department of Encephalopathy, Hubei Provincial Hospital of TCM, Wuhan, P.R. China
| | - Lili Zhang
- Department of Endocrinology and Metabolism, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Yuqing Zhang
- Department of Cardiovascular Medicine, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China
| | - Jiaqiang Zhou
- Department of Endocrinology and Metabolism, Sir Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine, Hangzhou, China
| | - Xinli Zhou
- Department of endocrinology and Metabolism, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
| | - Dalong Zhu
- Department of Endocrinology, Affiliated Drum Tower Hospital, Nanjing University School of Medicine, Nanjing, China
| | - Tiehong Zhu
- Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin, China
| | - Sheyu Li
- Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China
| | - Zhiming Zhu
- Department of Hypertension and Endocrinology, Army Medical University, Chongqing, China
- Chongqing Institute of Hypertension, Chongqing, China
| |
Collapse
|
2
|
Liu D, Chi Y, Song P, Zeng X, Du L, Chen Y, Li S. Risk factors, clinical manifestation, precaution, and management of monkeypox. J Evid Based Med 2022; 15:183-186. [PMID: 35996882 DOI: 10.1111/jebm.12490] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/25/2022] [Accepted: 07/27/2022] [Indexed: 01/11/2023]
Affiliation(s)
- Dan Liu
- Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China
| | - Yuan Chi
- Yealth Network, Beijing Yealth Technology Co., Ltd, Beijing, China
- Cochrane Campbell Global Ageing Partnership, London, UK
| | - Peige Song
- School of Public Health, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
| | - Xiantao Zeng
- Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - Liang Du
- Division of Guideline and Rapid Recommendation, Cochrane China Center, MAGIC China Center, Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China
| | - Yaolong Chen
- Key Laboratory of Evidence-Based Medicine and Knowledge Translation of Gansu Province, Lanzhou University, Lanzhou, China
- Evidence-based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China
- Guideline International Network Asia, Lanzhou, China
- World Health Organization (WHO) Collaborating Centre for Guideline Implementation and Knowledge Translation, Lanzhou, China
- Lanzhou University, an affiliate of the Cochrane China Network, Lanzhou, China
| | - Sheyu Li
- Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China
- Division of Guideline and Rapid Recommendation, Cochrane China Center, MAGIC China Center, Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China
| |
Collapse
|
3
|
Dix R, Straiton D, Metherall P, Laidlaw J, McLean L, Hayward A, Ginger G, Forrester L, O’Rourke P, Jefferies R. COVID-19: A systematic evaluation of personal protective equipment (PPE) performance during restraint. MEDICINE, SCIENCE, AND THE LAW 2021; 61:275-285. [PMID: 33715558 PMCID: PMC8490659 DOI: 10.1177/00258024211000805] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
BACKGROUND Restraint is widely practised within inpatient mental health services and is considered a higher-risk procedure for patients and staff. There is a sparsity of evidence in respect of the efficacy of personal protective equipment (PPE) used during restraint for reducing risk of infection. METHODS A series of choreographed restraint episodes were used to simulate contact contamination in research participants playing the roles of staff members and a patient. For comparison, one episode of simulated recording of physical observations was taken. Ultraviolet (UV) fluorescent material was used to track the simulated contact contamination, with analysis undertaken using established image registration techniques of UV photographs. This was repeated for three separate sets of PPE. RESULTS All three PPE sets showed similar performance in protecting against contamination transfer. For teams not utilising coveralls, this was dependent upon effective cleansing as part of doffing. There were similar patterns of contamination for restraint team members assigned to specific roles, with hands and upper torso appearing to be higher-risk areas. The restraint-related contamination was 23 times higher than that observed for physical observations. DISCUSSION A second layer of clothing that can be removed showed efficacy in reducing contact contamination. PPE fit to individual is important. Post-restraint cleansing procedures are currently inadequate, with new procedures for face and neck cleansing required. These findings leave scope for staff to potentially improve their appearance when donning PPE and engaging with distressed patients.
Collapse
Affiliation(s)
- Roland Dix
- Gloucestershire Health and Care NHS Foundation Trust, Montpellier Unit, Wotton Lawn Hospital, UK
| | - David Straiton
- Gloucestershire Health and Care NHS Foundation Trust, Montpellier Unit, Wotton Lawn Hospital, UK
| | - Peter Metherall
- Sheffield Teaching Hospitals NHS Foundation Trust, Northern General Hospital, UK
| | - James Laidlaw
- Gloucestershire Health and Care NHS Foundation Trust, Montpellier Unit, Wotton Lawn Hospital, UK
| | - Lisa McLean
- Gloucestershire Health and Care NHS Foundation Trust, Montpellier Unit, Wotton Lawn Hospital, UK
| | - Andy Hayward
- Gloucestershire Health and Care NHS Foundation Trust, Montpellier Unit, Wotton Lawn Hospital, UK
| | - Gary Ginger
- Gloucestershire Health and Care NHS Foundation Trust, Montpellier Unit, Wotton Lawn Hospital, UK
| | - Louise Forrester
- Gloucestershire Health and Care NHS Foundation Trust, Montpellier Unit, Wotton Lawn Hospital, UK
| | - Paul O’Rourke
- Gloucestershire Health and Care NHS Foundation Trust, Montpellier Unit, Wotton Lawn Hospital, UK
| | - Rob Jefferies
- Avon and Wiltshire Mental Health Partnership NHS Trust, UK
| |
Collapse
|
4
|
Li Y, Yang X, Yan P, Sun T, Zeng Z, Li S. Metformin in Patients With COVID-19: A Systematic Review and Meta-Analysis. Front Med (Lausanne) 2021; 8:704666. [PMID: 34490296 PMCID: PMC8416892 DOI: 10.3389/fmed.2021.704666] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2021] [Accepted: 07/29/2021] [Indexed: 02/05/2023] Open
Abstract
Importance/Background: The coronavirus disease (COVID-19) pandemic is a critical public health issue. Evidence has shown that metformin favorably influences COVID-19 outcomes. This study aimed to assess the benefits and risks of metformin in COVID-19 patients. Methods: We searched the PubMed, Embase, Cochrane Library, and Chinese Biomedical Literature Database from inception to February 18, 2021. Observational studies assessing the association between metformin use and the outcomes of COVID-19 patients were included. The primary outcome was mortality, and the secondary outcomes included intubation, deterioration, and hospitalization. Random-effects weighted models were used to pool the specific effect sizes. Subgroup analyses were conducted by stratifying the meta-analysis by region, diabetic status, the adoption of multivariate model, age, risk of bias, and timing for adding metformin. Results: We identified 28 studies with 2,910,462 participants. Meta-analysis of 19 studies showed that metformin is associated with 34% lower COVID-19 mortality [odds ratio (OR), 0.66; 95% confidence interval (CI), 0.56-0.78; I 2 = 67.9%] and 27% lower hospitalization rate (pooled OR, 0.73; 95% CI, 0.53-1.00; I 2 = 16.8%). However, we did not identify any subgroup effects. The meta-analysis did not identify statistically significant association between metformin and intubation and deterioration of COVID-19 (OR, 0.94; 95% CI, 0.77-1.16; I 2 = 0.0% for intubation and OR, 2.04; 95% CI, 0.65-6.34; I 2 = 79.4% for deterioration of COVID-19), respectively. Conclusions: Metformin use among COVID-19 patients was associated with a reduced risk of mortality and hospitalization. Our findings suggest a relative benefit for metformin use in nursing home and hospitalized COVID-19 patients. However, randomized controlled trials are warranted to confirm the association between metformin use and COVID-19 outcomes. Study Registration: The study was registered on the PROSPERO on Feb 23, 2021 (CRD42021238722).
Collapse
Affiliation(s)
- Yin Li
- “Double First-Class” Construction Office, West China Hospital, Sichuan University, Chengdu, China
| | - Xue Yang
- Department of Epidemiology and Biostatistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China
| | - Peijing Yan
- Department of Epidemiology and Biostatistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China
| | - Tong Sun
- Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, China
| | - Zhi Zeng
- Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China
| | - Sheyu Li
- Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China
- Department of Guideline and Rapid Recommendation, Chinese Evidence-Based Medicine Center, Cochrane China Center and MAGIC China Center, West China Hospital, Sichuan University, Chengdu, China
| |
Collapse
|
5
|
Li X, Zhang S, Zhou Y, Liu Y, Zhou Y, Li S, Su N. Deficiencies in Planning Interventional Trial Registration of COVID-19 in China. Front Med (Lausanne) 2021; 8:618185. [PMID: 33869242 PMCID: PMC8044513 DOI: 10.3389/fmed.2021.618185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2020] [Accepted: 03/09/2021] [Indexed: 02/05/2023] Open
Abstract
Background: The coronavirus disease 2019 (COVID-19) pandemic has affected the world since late 2019. The efforts to control the spread of the virus need to be supported by credible evidence. Therefore, we analyzed the rationality of the timeline and geographic distribution of COVID-19 trial registration in mainland China. Methods: We searched the Chinese Clinical Trial Registry (ChiCTR, http://www.chictr.org.cn/) and International Clinical Trials Registry Platform (ICTRP, https://www.who.int/ictrp/en/) using keywords including novel coronavirus, coronavirus pneumonia, 2019-nCoV, COVID-19, and SARS-COV-2 from 1 December 2019 to 27 April 2020 and included interventional randomized and non-randomized trials including patients with confirmed cases of COVID-19 in mainland China. The registered trials were reviewed, and data were independently extracted by two reviewers based on the inclusion criteria. Results: A total of 263 registered interventional trials were included in the study. We defined the sample size index (SI) as the total number of patients needed by the trials divided by the total number of patients diagnosed with COVID-19. A total of 84,341 patients had been diagnosed with COVID-19 in China as of 26 April 2020, and the included trials had a combined sample size of 31,156 patients (SI: 0.37). After control of the COVID-19 epidemic was achieved in China (February 18, 2020), the SI was 1.54, suggesting that the number of patients needed by the trials was greater than the number of newly diagnosed patients. The SIs in 8 out of 26 provinces in mainland China were >1. Conclusions: Our results suggested a clear over registration of COVID-19 trials in China, especially after control of the pandemic was achieved, preventing the generation of high-quality evidence.
Collapse
Affiliation(s)
- Xiaodan Li
- Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China
| | - Shengzhao Zhang
- Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, China
- West China School of Pharmacy, Sichuan University, Chengdu, China
| | - Yiling Zhou
- Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China
| | - Ying Liu
- Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, China
| | - Youlian Zhou
- Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China
| | - Sheyu Li
- Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China
- Department of Guideline and Rapid Recommendation, Cochrane China Center, MAGIC China Center, Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China
| | - Na Su
- Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, China
- West China School of Pharmacy, Sichuan University, Chengdu, China
| |
Collapse
|
6
|
Wen W, Zhang G, Luo S, Bai Z, Tao W, Guo M, He K, Jia S, Liu W, Zhang K, Weng J, Zhu S. Next-generation sequencing revealed influenza and Chlamydia infection in recurrent pneumonia in a patient who had recovered from COVID-19. PRECISION CLINICAL MEDICINE 2020; 3:294-296. [PMID: 35960663 PMCID: PMC7543505 DOI: 10.1093/pcmedi/pbaa033] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2020] [Accepted: 09/09/2020] [Indexed: 01/19/2023] Open
Affiliation(s)
- Wen Wen
- The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China
- Hefei National Laboratory for Physical Sciences at Microscale, the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230026, China
| | - Guorong Zhang
- Hefei National Laboratory for Physical Sciences at Microscale, the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230026, China
| | - Sihui Luo
- The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China
| | - Zhaoqing Bai
- Anqing Hospital Affiliated to Anhui Medical University (Anqing Municipal Hospital), Anqing 246003, China
| | - Wanyin Tao
- The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China
- Hefei National Laboratory for Physical Sciences at Microscale, the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230026, China
| | - Meng Guo
- Hefei National Laboratory for Physical Sciences at Microscale, the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230026, China
| | - Kaixin He
- Hefei National Laboratory for Physical Sciences at Microscale, the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230026, China
| | - Shuafang Jia
- Anqing Hospital Affiliated to Anhui Medical University (Anqing Municipal Hospital), Anqing 246003, China
| | - Wei Liu
- Anqing Hospital Affiliated to Anhui Medical University (Anqing Municipal Hospital), Anqing 246003, China
| | - Kaiguang Zhang
- The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China
| | - Jianping Weng
- The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China
| | - Shu Zhu
- The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China
- Hefei National Laboratory for Physical Sciences at Microscale, the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230026, China
- School of Data Science, University of Science and Technology of China, Hefei 230026, China
- CAS Centre for Excellence in Cell and Molecular Biology, University of Science and Technology of China, Hefei 230026, China
| |
Collapse
|
7
|
Wang D, You Y, Zhou X, Zong Z, Huang H, Zhang H, Yong X, Cheng Y, Yang L, Guo Q, Long Y, Liu Y, Huang J, Du L. Selection of homemade mask materials for preventing transmission of COVID-19: A laboratory study. PLoS One 2020; 15:e0240285. [PMID: 33057355 PMCID: PMC7561133 DOI: 10.1371/journal.pone.0240285] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2020] [Accepted: 09/24/2020] [Indexed: 02/05/2023] Open
Abstract
The Coronavirus Disease 2019 (COVID-19) has swept the whole world with high mortality. Since droplet transmission is the main route of transmission, wearing a mask serves as a crucial preventive measure. However, the virus has spread quite quickly, causing severe mask shortage. Finding alternative materials for homemade masks while ensuring the significant performance indicators will help alleviate the shortage of masks. Referring to the national standard for the "Surgical Mask" of China, 17 materials to be selected for homemade masks were tested in four key indicators: pressure difference, particle filtration efficiency, bacterial filtration efficiency and resistance to surface wetting. Eleven single-layer materials met the standard of pressure difference (≤49 Pa), of which 3 met the standard of resistance to surface wetting (≥3), 1 met the standard of particle filtration efficiency (≥30%), but none met the standard of bacterial filtration efficiency (≥95%). Based on the testing results of single-layer materials, fifteen combinations of paired materials were tested. The results showed that three double-layer materials including double-layer medical non-woven fabric, medical non-woven fabric plus non-woven shopping bag, and medical non-woven fabric plus granular tea towel could meet all the standards of pressure difference, particle filtration efficiency, and resistance to surface wetting, and were close to the standard of the bacterial filtration efficiency. In conclusion, if resources are severely lacking and medical masks cannot be obtained, homemade masks using available materials, based on the results of this study, can minimize the chance of infection to the maximum extent.
Collapse
Affiliation(s)
- Dijia Wang
- Department of Equipment, West China Hospital, Sichuan University, Chengdu, China
| | - Yanjun You
- Sichuan Testing Center of Medical Devices, Chengdu, China
| | - Xiaoli Zhou
- Department of Nursing, West China Hospital, Sichuan University, Chengdu, China
| | - Zhiyong Zong
- Department of Infection Management, West China Hospital, Sichuan University, Chengdu, China
| | - Hao Huang
- Department of Nursing, West China Hospital, Sichuan University, Chengdu, China
| | - Hui Zhang
- Department of Infection Management, West China Hospital, Sichuan University, Chengdu, China
| | - Xin Yong
- Department of Equipment, West China Hospital, Sichuan University, Chengdu, China
| | - Yifan Cheng
- Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China
| | - Liu Yang
- Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China
| | - Qiong Guo
- Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China
| | - Youlin Long
- Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China
| | - Yan Liu
- Emergency Department of West China Hospital, Institute of Disaster Medicine, Department of Emergency and Trauma Nursing, West China Nursing School, Sichuan University, Chengdu, China
| | - Jin Huang
- West China Hospital, Sichuan University, Chengdu, China
| | - Liang Du
- Center for Medical Device Supervision and Evaluation, Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China
| |
Collapse
|